Osteogenesis Imperfecta Clinical Trial
Official title:
Whole Body Vibration as an Osteogenic Treatment for Children With Osteogenesis Imperfecta With Limited Mobility: A Randomised Controlled Pilot Trial
Verified date | January 2017 |
Source | Birmingham Children's Hospital NHS Foundation Trust |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Children with osteogenesis imperfecta (OI) have impaired bone strength, fractures, weak muscles and limited mobility. Mild to moderate forms of OI (type 1 and 4) may benefit from muscle training that leads to secondary improvement in bone strength (osteogenic treatment). Recent studies in children with cerebral palsy but also OI suggest that Whole Body Vibration Training (WBVT) improves mobility and also bone strength. No randomized controlled trials exist in OI children. This randomized controlled pilot study assesses the effect of 5 months WBVT (2 x 9min/day) on muscle function, mobility, bone structure and density. 24 children >5 years with OI type 1 and 4 with limited mobility (CHAQ Score ≥0.13) will be randomized into a WBVT group and a control group matched by gender and pubertal stage. Main outcome measure is the change in tibial volumetric BMD, secondary outcomes include a variety of bone, mobility and dynamic muscle function variables.
Status | Completed |
Enrollment | 24 |
Est. completion date | January 18, 2016 |
Est. primary completion date | November 18, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 5 Years to 16 Years |
Eligibility |
Inclusion Criteria: Patients with mild OI (type 1 and 4; >5y of age) who need to be at least partly ambulant and have a CHAQ score of greater than 0.13, constituting at least mild disability. Minimum requirement is the ability to rise from a chair. Informed consent is required from the participant and/or parent/guardian. Exclusion Criteria: - On bisphosphonate treatment for less than 2years (since mobility usually improves during the initial phase treatment). - Finished bisphosphonate therapy less than 6 months ago - Recent lower limb fracture <3months ago, or upper limb fracture which is still in plaster. - Heart or lung disease, use of steroids (oral, systemic, topical or inhaled, for more than 3 weeks in the last 12 months) or any other bone-active treatment. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Birmingham Children's Hospital | Birmingham |
Lead Sponsor | Collaborator |
---|---|
Birmingham Children's Hospital NHS Foundation Trust | Royal Manchester Children' s Hospital, Manchester, University of Sheffield |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Does WBVT increase bone density at the distal tibia | Trabecular volumetric BMD measured at the distal tibia (4% of tibia length) | 5 months | |
Secondary | Does WBVT result in an increase in dynamic muscle function | Jumping Mechanography (single 2-leg jump, multiple one leg hop, chair and heel rise test) | 5 months | |
Secondary | Does WBVT result in an increase in muscle mass | Muscle mass measured by DXA | 5 months | |
Secondary | Does WBVT result in an increase in density | Bone density measured by DXA | 5 months | |
Secondary | Does WBVT result in an increase in density of the tibia | Bone density measured by pQCT | 5 months | |
Secondary | Does WBVT result in an increase in bone geometry | Bone size measured by pQCT | 5 months | |
Secondary | Does WBVT result in an increase in 6-minute walking distance | six minute walk tests | 5 months | |
Secondary | Does WBVT result in improved disability | CHAQ disability score | 5 months | |
Secondary | Does WBVT result in improved balance | Balance (sway area measured by mechanography) | 5 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03557567 -
NGS Strategy Effectiveness in Molecular Diagnosis
|
||
Not yet recruiting |
NCT05559801 -
Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02531087 -
Urinary Biomarkers of OI Pathobiology
|
||
Completed |
NCT01713231 -
Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta
|
Phase 4 | |
Completed |
NCT00655681 -
Prevention of Post Operative Bone Loss in Children
|
N/A | |
Recruiting |
NCT06065111 -
Study of Osteogenesis Imperfecta Tendon
|
||
Withdrawn |
NCT03216486 -
An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta
|
Phase 2 | |
Recruiting |
NCT06086613 -
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04009733 -
Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study
|
N/A | |
Completed |
NCT04231916 -
High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta
|
N/A | |
Active, not recruiting |
NCT02814591 -
Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
|
||
Completed |
NCT00982124 -
An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT00001305 -
Growth Hormone Therapy in Osteogenesis Imperfecta
|
Phase 3 | |
Completed |
NCT04119388 -
Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta
|
N/A | |
Terminated |
NCT01679080 -
The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
|
Phase 2 | |
Completed |
NCT00106028 -
Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children
|
Phase 3 | |
Recruiting |
NCT04152551 -
Effects of Bisphosphonates on OI-Related Hearing Loss
|
Phase 4 | |
Completed |
NCT00705120 -
Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation
|
Phase 1 | |
Recruiting |
NCT04169568 -
Osteogenesis Imperfecta Blood Pressure Study
|
||
Completed |
NCT03064074 -
Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta
|
Phase 1 |